The Filings Report

Vaxcyte, Inc. Common Stock

PCVXNasdaqCIK 1649094Healthcare / Biotechnologyfiscal year ends December30 quarters since 2019

Revenue, Q2 FY2026
—
no year-earlier figure
Net income
−$284M
−70.7% on Q2 FY2025
Free cash flow
−$237M
−92.5% on Q2 FY2025
Diluted EPS
$-1.97
−61.5% on Q2 FY2025
Revenue, TTM
—
trailing four quarters
Net margin, TTM
—
net income −$1.1B
Free cash flow, TTM
−$894M
−$881M less $13M capex
Cash and equivalents
$183M
long-term debt —, Jun 30, 2026
Shares, 12-month change
+14.6%
149M shares, Jun 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$9.0B
at the close, buybacks

Latest quarter Q2 FY2026, filed August 5, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, Vaxcyte, Inc. Common Stock reported no revenue line, and net loss of $284M (−70.7%). Free cash flow, operating cash flow less capital expenditures, was −$237M (−$232M less $4M). Diluted earnings per share were $-1.97.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of August 5, 2026.

Revenue and net incomeRevenueNet income
−$400M−$300M−$200M−$100M$0$100MQ3'22, Net income: −$58MQ3'22Q4'22, Net income: −$78MQ4'22Q1'23, Net income: −$60MQ1'23Q2'23, Net income: −$68MQ2'23Q3'23, Net income: −$93MQ3'23Q4'23, Net income: −$181MQ4'23Q1'24, Net income: −$95MQ1'24Q2'24, Net income: −$129MQ2'24Q3'24, Net income: −$103MQ3'24Q4'24, Net income: −$137MQ4'24Q1'25, Net income: −$141MQ1'25Q2'25, Net income: −$167MQ2'25Q3'25, Net income: −$213MQ3'25Q4'25, Net income: −$247MQ4'25Q1'26, Net income: −$321MQ1'26Q2'26, Net income: −$284MQ2'26−$400M−$300M−$200M−$100M$0$100MQ3'22, Net income: −$58MQ4'22, Net income: −$78MQ4'22Q1'23, Net income: −$60MQ2'23, Net income: −$68MQ2'23Q3'23, Net income: −$93MQ4'23, Net income: −$181MQ4'23Q1'24, Net income: −$95MQ2'24, Net income: −$129MQ2'24Q3'24, Net income: −$103MQ4'24, Net income: −$137MQ4'24Q1'25, Net income: −$141MQ2'25, Net income: −$167MQ2'25Q3'25, Net income: −$213MQ4'25, Net income: −$247MQ4'25Q1'26, Net income: −$321MQ2'26, Net income: −$284MQ2'26

Net income losses drawn in red.

Free cash flow
−$300M−$200M−$100M$0$100MQ3'22, Free cash flow: −$39MQ3'22Q4'22, Free cash flow: −$66MQ4'22Q1'23, Free cash flow: −$53MQ1'23Q2'23, Free cash flow: −$61MQ2'23Q3'23, Free cash flow: −$65MQ3'23Q4'23, Free cash flow: −$134MQ4'23Q1'24, Free cash flow: −$165MQ1'24Q2'24, Free cash flow: −$129MQ2'24Q3'24, Free cash flow: −$66MQ3'24Q4'24, Free cash flow: −$115MQ4'24Q1'25, Free cash flow: −$172MQ1'25Q2'25, Free cash flow: −$123MQ2'25Q3'25, Free cash flow: −$147MQ3'25Q4'25, Free cash flow: −$227MQ4'25Q1'26, Free cash flow: −$283MQ1'26Q2'26, Free cash flow: −$237MQ2'26−$300M−$200M−$100M$0$100MQ3'22, Free cash flow: −$39MQ4'22, Free cash flow: −$66MQ4'22Q1'23, Free cash flow: −$53MQ2'23, Free cash flow: −$61MQ2'23Q3'23, Free cash flow: −$65MQ4'23, Free cash flow: −$134MQ4'23Q1'24, Free cash flow: −$165MQ2'24, Free cash flow: −$129MQ2'24Q3'24, Free cash flow: −$66MQ4'24, Free cash flow: −$115MQ4'24Q1'25, Free cash flow: −$172MQ2'25, Free cash flow: −$123MQ2'25Q3'25, Free cash flow: −$147MQ4'25, Free cash flow: −$227MQ4'25Q1'26, Free cash flow: −$283MQ2'26, Free cash flow: −$237MQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$500M$1.0B$1.5BQ3'22, Cash and equivalents: $278MQ3'22Q4'22, Cash and equivalents: $835MQ4'22Q1'23, Cash and equivalents: $380MQ1'23Q2'23, Cash and equivalents: $531MQ2'23Q3'23, Cash and equivalents: $545MQ3'23Q4'23, Cash and equivalents: $397MQ4'23Q1'24, Cash and equivalents: $612MQ1'24Q2'24, Cash and equivalents: $519MQ2'24Q3'24, Cash and equivalents: $1.1BQ3'24Q4'24, Cash and equivalents: $388MQ4'24Q1'25, Cash and equivalents: $347MQ1'25Q2'25, Cash and equivalents: $307MQ2'25Q3'25, Cash and equivalents: $281MQ3'25Q4'25, Cash and equivalents: $174MQ4'25Q1'26, Cash and equivalents: $261MQ1'26Q2'26, Cash and equivalents: $183MQ2'26$0$500M$1.0B$1.5BQ3'22, Cash and equivalents: $278MQ4'22, Cash and equivalents: $835MQ4'22Q1'23, Cash and equivalents: $380MQ2'23, Cash and equivalents: $531MQ2'23Q3'23, Cash and equivalents: $545MQ4'23, Cash and equivalents: $397MQ4'23Q1'24, Cash and equivalents: $612MQ2'24, Cash and equivalents: $519MQ2'24Q3'24, Cash and equivalents: $1.1BQ4'24, Cash and equivalents: $388MQ4'24Q1'25, Cash and equivalents: $347MQ2'25, Cash and equivalents: $307MQ2'25Q3'25, Cash and equivalents: $281MQ4'25, Cash and equivalents: $174MQ4'25Q1'26, Cash and equivalents: $261MQ2'26, Cash and equivalents: $183MQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Vaxcyte, Inc. Common Stock income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 7, 2025Q4 FY2024ended Dec 31, 2024filed Feb 25, 2025Q3 FY2024ended Sep 30, 2024filed Nov 5, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue—————————
Cost of revenue—————————
Gross profit—————————
Research and development268313242210194148134117+37.9%
Selling, general and administrative3533323232332923+9.0%
Operating income(303)(346)(274)(242)(226)(181)(162)(140)−33.8%
Other income (expense)1825283060402537−69.0%
Pretax income—————————
Income tax00000000—
Net income(284)(321)(247)(213)(167)(141)(137)(103)−70.7%
Diluted EPS ($)(1.97)(2.30)—(1.56)(1.22)(1.04)—(0.83)−61.5%
Diluted shares (millions)144140—136136136—124—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Vaxcyte, Inc. Common Stock balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 7, 2025Q4 FY2024ended Dec 31, 2024filed Feb 25, 2025Q3 FY2024ended Sep 30, 2024filed Nov 5, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents1832611742813073473881,050−40.3%
Short-term investments1,3041,4761,3871,4301,3551,3251,3591,130−3.8%
Total current assets1,5531,8131,6271,7671,7161,7171,7882,214−9.5%
Total assets3,1383,3483,0033,1723,3053,3783,5113,560−5.1%
Total current liabilities27124220620015497140124+75.6%
Long-term debt—————————
Total liabilities380352317279234178205142+62.5%
Stockholders’ equity2,7582,9962,6862,8933,0713,2003,3063,418−10.2%
Shares outstanding (millions)149144144131130129129125—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Vaxcyte, Inc. Common Stock cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 7, 2025Q4 FY2024ended Dec 31, 2024filed Feb 25, 2025Q3 FY2024ended Sep 30, 2024filed Nov 5, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow(232)(281)(225)(143)(121)(166)(111)(61)−91.9%
Capital expenditures42342545+138.5%
Free cash flow (CFO − capex)(237)(283)(227)(147)(123)(172)(115)(66)−92.5%
Depreciation and amortization33733332+4.3%
Share repurchases—————————
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 24, 2026.

Income statement

Vaxcyte, Inc. Common Stock income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 25, 2025FY2023ended Dec 31, 2023filed Feb 27, 2024FY2022ended Dec 31, 2022filed Feb 27, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Mar 29, 2021FY2019ended Dec 31, 2019filed Aug 12, 2020FY2018ended Dec 31, 2018filed Aug 12, 2020
Revenue————————
Cost of revenue————————
Gross profit————————
Research and development79447733216978744630
Selling, general and administrative129936140251695
Operating income(924)(570)(468)(232)(104)(90)(54)(36)
Other income (expense)1571066694046
Pretax income————————
Income tax000—————
Net income(767)(464)(402)(223)(100)(89)(50)(29)
Diluted EPS ($)(5.63)(3.80)(4.14)(3.44)(1.93)(3.02)——
Diluted shares (millions)13612297655230——

Balance sheet

Vaxcyte, Inc. Common Stock balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 25, 2025FY2023ended Dec 31, 2023filed Feb 27, 2024FY2022ended Dec 31, 2022filed Feb 27, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Mar 29, 2021FY2019ended Dec 31, 2019filed Aug 12, 2020FY2018ended Dec 31, 2018filed Aug 12, 2020
Cash and equivalents1743883978356938659—
Short-term investments1,3871,35968397177———
Total current assets1,6271,7881,09694325638962—
Total assets3,0033,5111,4081,00632439366—
Total current liabilities20614014541294711—
Long-term debt————————
Total liabilities31720516753404712—
Stockholders’ equity2,6863,3061,240954284346(106)(58)
Shares outstanding (millions)144129108805651——

Cash flow statement

Vaxcyte, Inc. Common Stock cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 25, 2025FY2023ended Dec 31, 2023filed Feb 27, 2024FY2022ended Dec 31, 2022filed Feb 27, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Mar 29, 2021FY2019ended Dec 31, 2019filed Aug 12, 2020FY2018ended Dec 31, 2018filed Aug 12, 2020
Operating cash flow(656)(453)(297)(171)(121)(47)(47)(30)
Capital expenditures14221667112
Free cash flow (CFO − capex)(669)(475)(313)(176)(128)(48)(48)(32)
Depreciation and amortization167332111
Share repurchases————————
Dividends paid————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 3, 2024 to November 3, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$5M
11 sales by 3 insiders; officers and directors $5M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$12M
53 sales by 5 insiders; officers and directors $12M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 5, 2026Wassil JimEVP, Chief Scientific Ofc, COOoption exercise18,000$5.35$96K163,435Oct 7, 2026
Oct 5, 2026Wassil JimEVP, Chief Scientific Ofc, COOopen-market sale10b5-118,000$86.74$2M145,435Oct 7, 2026
Oct 5, 2026Cowan ElviaSVP, Finance & CAOoption exercise19,000$25.92$492K46,860Oct 7, 2026
Oct 5, 2026Cowan ElviaSVP, Finance & CAOopen-market sale10b5-119,000$86.74$2M27,860Oct 7, 2026
Oct 1, 2026Wassil JimEVP, Chief Scientific Ofc, COOoption exercise2,250$5.35$12K147,685Oct 2, 2026
Oct 1, 2026Wassil JimEVP, Chief Scientific Ofc, COOopen-market sale10b5-12,155$56.65$122K145,530Oct 2, 2026
Oct 1, 2026Wassil JimEVP, Chief Scientific Ofc, COOopen-market sale10b5-195$57.09$5K145,435Oct 2, 2026
Sep 9, 2026Wassil JimEVP, Chief Scientific Ofc, COOopen-market sale1,334$59.52$79K145,435Sep 9, 2026
Sep 8, 2026Pickering GrantCHIEF EXECUTIVE OFFICER, Directortax withholding17,056$60.36$1M429,902Sep 9, 2026
Sep 8, 2026Guggenhime AndrewPRESIDENT AND CFOtax withholding7,155$60.36$432K95,316Sep 9, 2026
Sep 8, 2026Dhaliwal Harpreet S.Chief Technical Ops Officertax withholding7,651$60.36$462K68,085Sep 9, 2026
Sep 8, 2026Cowan ElviaSVP, Finance & CAOtax withholding1,327$60.36$80K27,860Sep 9, 2026
Sep 8, 2026Wassil JimEVP, Chief Scientific Ofc, COOtax withholding5,459$60.36$330K146,769Sep 9, 2026
Sep 4, 2026Wassil JimEVP, Chief Scientific Ofc, COOopen-market sale1,381$61.16$84K152,228Sep 9, 2026
Sep 4, 2026Jodar LuisChief Medical Officeraward52,632$0.00—52,632Sep 9, 2026
Sep 2, 2026Wassil JimCHIEF OPERATING OFFICERtax withholding1,432$61.58$88K153,609Sep 2, 2026
Sep 2, 2026Pickering GrantCHIEF EXECUTIVE OFFICER, Directortax withholding3,427$61.58$211K446,958Sep 2, 2026
Sep 2, 2026Guggenhime AndrewPRESIDENT AND CFOtax withholding1,432$61.58$88K102,471Sep 2, 2026
Sep 2, 2026Dhaliwal Harpreet S.Chief Technical Ops Officertax withholding659$61.58$41K75,736Sep 2, 2026
Sep 2, 2026Cowan ElviaSVP, Finance & CAOtax withholding326$61.58$20K29,187Sep 2, 2026
Sep 1, 2026Wassil JimCHIEF OPERATING OFFICERoption exercise2,250$5.35$12K158,518Sep 2, 2026
Sep 1, 2026Wassil JimCHIEF OPERATING OFFICERopen-market sale1,537$60.89$94K156,981Sep 2, 2026
Sep 1, 2026Wassil JimCHIEF OPERATING OFFICERopen-market sale713$61.48$44K156,268Sep 2, 2026
Sep 1, 2026Wassil JimCHIEF OPERATING OFFICERopen-market sale924$60.95$56K155,344Sep 2, 2026
Sep 1, 2026Wassil JimCHIEF OPERATING OFFICERopen-market sale303$61.42$19K155,041Sep 2, 2026

Full insider history for Vaxcyte, Inc. Common Stock, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
Vaxcyte, Inc., CIK 1649094 on EDGAR
Extract generated
November 4, 2026
Withheld
1 line-years whose four quarters do not sum to the filed year: depreciation amortization FY2023
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: not filed
Cost of revenue: not filed
Gross profit: not filed
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: GeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense, OtherNonoperatingIncomeExpense
Pretax income: not filed
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: not filed
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationAndAmortization, DepreciationDepletionAndAmortization
Share repurchases: not filed
Dividends paid: not filed

The data

The statements on this page as files, generated November 4, 2026.

JSON file
/data/financials/PCVX.json